Document Detail


A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne).
MedLine Citation:
PMID:  10438376     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
To develop a vaccine against cytomegalovirus (CMV), a canarypox virus (ALVAC) expressing CMV glycoprotein (gB) was evaluated alone or in combination with a live, attenuated CMV vaccine (Towne). Three doses of 106.5 TCID50 of ALVAC-CMV(gB) induced very low neutralizing or ELISA antibodies in most seronegative adults. However, to determine whether ALVAC-CMV(gB) could prime for antibody responses, 20 seronegative adults randomly received either 106.8 TCID50 of ALVAC-CMV(gB) or 106.8 TCID50 of ALVAC-RG, expressing the rabies glycoprotein, administered at 0 and 1 month, with all subjects receiving a dose of 103.5 pfu of the Towne vaccine at 90 days. For subjects primed with ALVAC-CMV(gB), neutralizing titers and ELISA antibodies to CMV(gB) developed sooner, were much higher, and persisted longer than for subjects primed with ALVAC-RG. All vaccines were well tolerated. These results demonstrate that ALVAC-CMV(gB) primes the immune system and suggest a combined-vaccine strategy to induce potentially protective levels of neutralizing antibodies.
Authors:
S P Adler; S A Plotkin; E Gonczol; M Cadoz; C Meric; J B Wang; P Dellamonica; A M Best; J Zahradnik; S Pincus; K Berencsi; W I Cox; Z Gyulai
Related Documents :
1950096 - Immune response to rabies vaccine in thai dogs: a preliminary report.
2409716 - Cross protection of mice against different rabies virus isolates.
12009276 - Rabies dna vaccination of non-human primates: post-exposure studies using gene gun meth...
3264616 - Ecology and epidemiology of raccoon rabies.
21343146 - An ad5-vectored hiv-1 vaccine elicits cell-mediated immunity but does not affect diseas...
14733736 - Avidity maturation following immunization with two human cytomegalovirus (cmv) vaccines...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  The Journal of infectious diseases     Volume:  180     ISSN:  0022-1899     ISO Abbreviation:  J. Infect. Dis.     Publication Date:  1999 Sep 
Date Detail:
Created Date:  1999-09-23     Completed Date:  1999-09-23     Revised Date:  2008-08-26    
Medline Journal Info:
Nlm Unique ID:  0413675     Medline TA:  J Infect Dis     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  843-6     Citation Subset:  AIM; IM    
Affiliation:
Medical College of Virginia/Virginia Commonwealth University, Richmond, VA 23298-0163, USA. SADLER@HSC.VCU.EDU
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antibodies, Viral / blood
Antibody Formation
Avipoxvirus / genetics,  immunology*
Cytomegalovirus / genetics,  immunology*
Cytomegalovirus Infections / immunology*,  prevention & control
Double-Blind Method
Enzyme-Linked Immunosorbent Assay
Female
Genetic Vectors
Humans
Male
Middle Aged
Vaccines, Attenuated / adverse effects,  immunology*
Viral Envelope Proteins / immunology*
Viral Vaccines / adverse effects,  immunology*
Chemical
Reg. No./Substance:
0/ALVAC vaccine; 0/Antibodies, Viral; 0/Vaccines, Attenuated; 0/Viral Envelope Proteins; 0/Viral Vaccines; 0/glycoprotein B, Simplexvirus

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High prevalence of TT virus viremia in italian patients, regardless of age, clinical diagnosis, and ...
Next Document:  Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after trea...